Moderna’s vaccine approved in turn for children under 12

Moderna’s Spikevax vaccine against Covid-19 will now also be used for children aged 6 to 11, Swissmedic said. Compared with adults and adolescents 12 years and older, children 6 years of age or older will receive two half doses of the vaccine four weeks apart. The main study carried out on children aged 6 to 11 showed that the immune response triggered by the vaccine against the SARS-CoV-2 virus is comparable to that observed in young adults, Swissmedic said on Friday.

The most common side effects (pain, redness or swelling at the injection site, fatigue, headache, chills or nausea) are also similar to those seen in adolescents and young adults. Fever occurs more often in children, while muscle and joint pain are less common. Mild to moderate in nature, these side effects usually subsided after a few days.

Read also: What vaccine strategy for the future?

Vaccination can especially benefit children who suffer from underlying pathologies and therefore run an increased risk of presenting a severe form of Covid-19. The safety, efficacy and quality of all coronavirus vaccines given to children and adults continue to be closely monitored around the world, Swissmedic points out. Moderna has already received approval for a two-dose primary series in children aged 6 to 11 years in more than 35 countries, including Australia, Canada, the European Union and the United Kingdom.

Read also: Switzerland promises to help with anti-covid vaccines

Leave a Comment